Gallo P - Search Results

1

VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.

Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, Kober L, White HD, Swedberg K, Leimberger JD, Gallo P, Sellers MA, Edwards S, Henis M, Califf RM; VALIANT Investigators. Velazquez EJ, et al. Among authors: gallo p. Eur J Heart Fail. 2003 Aug;5(4):537-44. doi: 10.1016/s1388-9842(03)00112-0. Eur J Heart Fail. 2003. PMID: 12921816 Free article.

2

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Pfeffer MA, et al. Among authors: gallo p. Am Heart J. 2000 Nov;140(5):727-50. doi: 10.1067/mhj.2000.108832. Am Heart J. 2000. PMID: 11054617

3

Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults.

Bronsky EA, Grossman J, Henis MJ, Gallo PP, Yegen U, Della Cioppa G, Kottakis J, Mehra S. Bronsky EA, et al. Among authors: gallo pp. Curr Med Res Opin. 2004;20(2):131-7. doi: 10.1185/030079903125002793. Curr Med Res Opin. 2004. PMID: 15006006

4

Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.

Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ. Uno H, et al. Among authors: gallo p. J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30. J Clin Oncol. 2014. PMID: 24982461 Free PMC article.

5

Alternative views on setting clinical trial futility criteria.

Gallo P, Mao L, Shih VH. Gallo P, et al. J Biopharm Stat. 2014;24(5):976-93. doi: 10.1080/10543406.2014.932285. J Biopharm Stat. 2014. PMID: 24933121

6

An additive boundary for group sequential designs with connection to conditional error.

Xi D, Gallo P. Xi D, et al. Among authors: gallo p. Stat Med. 2019 Oct 15;38(23):4656-4669. doi: 10.1002/sim.8325. Epub 2019 Jul 23. Stat Med. 2019. PMID: 31338847

7

Center-weighting issues in multicenter clinical trials.

Gallo PP. Gallo PP. J Biopharm Stat. 2000 May;10(2):145-63. doi: 10.1081/BIP-100101019. J Biopharm Stat. 2000. PMID: 10803722

8

Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.

Gallo P, Anderson K, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Gallo P, et al. J Biopharm Stat. 2010 Nov;20(6):1115-24. doi: 10.1080/10543406.2010.514452. J Biopharm Stat. 2010. PMID: 21058107

9

Adaptive designs: The Swiss Army knife among clinical trial designs?

Bretz F, Gallo P, Maurer W. Bretz F, et al. Among authors: gallo p. Clin Trials. 2017 Oct;14(5):417-424. doi: 10.1177/1740774517699406. Epub 2017 Mar 22. Clin Trials. 2017. PMID: 28982262 Review.

10

Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.

Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J; PhRMA Working Group. Gallo P, et al. J Biopharm Stat. 2006 May;16(3):275-83; discussion 285-91, 293-8, 311-2. doi: 10.1080/10543400600614742. J Biopharm Stat. 2006. PMID: 16724485

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,008 results

Search Page